1 |
Alamri S,Badah MZ,Zorgi S,et al. Disease prognosis and therapeutic strategies in patients with advanced non-small cell lung cancer(NSCLC): A 6-year epidemiological study between 2015-2021[J].Transl Cancer Res, 2024, 13(2): 762-770.
|
2 |
姜 露, 周 菊, 毛 杨, 等. 单细胞和bulk RNA 测序的综合分析预测肺鳞状细胞癌治疗反应和预后[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(4): 535-542.
|
3 |
吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
4 |
Araghi M,Mannani R,Heidarnejad Maleki A,et al. Recent advances in non-small cell lung cancer targeted therapy; an update review[J]. Cancer Cell Int, 2023, 23(1): 162-186.
|
5 |
陈 景, 李斯妮, 李健和, 等. 免疫靶向药物治疗非小细胞肺癌的最新研究进展[J]. 肿瘤药学, 2023, 13(1): 11-16.
|
6 |
Zhao Y, Guo S, Deng J, et al. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment[J]. Int J Biol Sci, 2022, 18(9): 3845-3858.
|
7 |
Yoon HY, Ryu JS, Sim YS, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma:A multi-centre Korean study[J]. PLoS One, 2020, 15(2): e0228925.
|
8 |
Liu CY, Lin HF, Lai WY, et al. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers[J]. J Chin Med Assoc, 2022, 85(4): 409-413.
|
9 |
Batra U,Biswas B,Prabhash K,et al. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma nonsmall-cell lung cancer[J]. BMJ Open Respir Res, 2023, 10(1):e001492.
|
10 |
Khaddour K, Jonna S, Deneka A, et al. Targeting the epidermal growth factor receptor in EGFR-mutated lung cancer: Current and emerging therapies[J]. Cancers (Basel), 2021, 13(13): 3164-3186.
|
11 |
Ullas B, Shrinidhi N, Mansi S, et al. All EGFR mutations are(not) created equal: Focus on uncommon EGFR mutations[J]. J Cancer Res Clin Oncol, 2023, 149(4): 1541-1549.
|
12 |
Winfree KB,Molife C,Peterson PM,et al. Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations[J]. Future Oncol,2021, 17(22): 2867-2881.
|
13 |
Tian Y, Zhao J, Ren P, et al. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma[J]. PLoS One, 2018, 13(11): e0201682.
|
14 |
Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
|
15 |
Cheng WL, Feng PH, Lee KY, et al. The role of EREG/EGFR pathway in tumor progression[J]. Int J Mol Sci, 2021, 22(23):12828-12864.
|
16 |
Ramani S, Samant S, Manohar SM. The story of EGFR: From signaling pathways to a potent anticancer target[J]. Future Med Chem, 2022, 14(17): 1267-1288.
|
17 |
Zuo Y, Liu Q, Li N, et al. Optimal 18F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: A multicentric study[J]. Front Oncol, 2023, 13: 1173355-1173371.
|
18 |
Tan J,Hu C,Deng P,et al. The predictive values of advanced nonsmall cell lung cancer patients harboring uncommon EGFR mutations-The mutation patterns, use of different generations of EGFR-TKIs, and concurrent genetic alterations[J]. Front Oncol,2021, 11: 646577-646590.
|
19 |
孙文佳, 岳君秋, 王满香. EGFR 罕见突变非小细胞肺癌患者的临床病理特征及治疗效果[J]. 肿瘤防治研究, 2023, 50(12):1221-1226.
|
20 |
Yu X, Sheng J, Pan G, et al. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases[J]. Int J Cancer, 2021,149(5): 1121-1128.
|
21 |
Wang Y, Yuan X, Yang M, et al. Efficacy of icotinib, an EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients with Exon 19 deletion and Exon 21 L858R: A retrospective analysis in China[J]. Pharmacology, 2021, 106(11-12): 658-666.
|
22 |
Ju JS,Huang AC,Tung PH,et al. Brain metastasis,EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC[J]. Sci Rep, 2023,13(1): 20323-20331.
|
23 |
Morita C, Yoshida T, Shirasawa M, et al. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions[J]. Sci Rep, 2021, 11(1): 18762-18767.
|
24 |
Park S, Lee SY, Kim D, et al. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types[J]. BMC Cancer, 2021, 21(1): 52-59.
|
25 |
Skrickova J, Pesek M, Opalka P, et al. Prognostic value of EGFR Exon-20 insertions in czech patients with advanced non-small cell lung cancer[J]. Anticancer Res, 2021, 41(11): 5625-5634.
|
26 |
Passaro A, Prelaj A, Bonanno L, et al. Activity of EGFR TKIs in caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations[J]. Clin Lung Cancer, 2019, 20(2):e186-e194.
|
27 |
Koopman B,Cajiao Garcia BN, Kuijpers CCHJ, et al. A nationwide study on the impact of routine testing for EGFR mutations in advanced NSCLC reveals distinct survival patterns based on?EGFR? mutation subclasses[J]. Cancers (Basel), 2021, 13(14): 3641-3666.
|